Dizal Pharmaceutical: The company received a $600 million upfront payment from AstraZeneca.

Dizal Pharmaceutical announced that the company signed a License Agreement with AstraZeneca on July 14, 2026, granting AstraZeneca the exclusive rights to develop and commercialize Sunvozertinib worldwide, and the agreement officially took effect on August 31, 2026. Recently, the company has received a $600 million upfront payment from AstraZeneca.